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ABSTRACT 
 
Knowledge of the timing of mother-to-child transmission (MTCT) of HIV-1 is an 
important issue in reducing the risk of infant infection. Prior to giving birth therefore an 
HIV-1 positive mother should be provided with anti-HIV-1 drugs (antiretrovirals) during 
the shortest time possible to ensure both efficacy and minimal toxicity of the 
antiretrovirals to the newborn. However, in the absence of timeous administration of 
nevirapine (NVP) or zidovudine (AZT) to the mother at the onset of labour, infants are 
given post-exposure prophylaxis (PEP). Despite antiviral prophylaxis some infants still 
become infected. In an attempt to mimic the in vivo scenario we investigated, in Chapter 
Three, the replication ability of a primary isolate (M502L) in peripheral blood 
mononuclear cells (PBMC) isolated from healthy donors exposed to different 
concentrations of NVP or AZT either prior to or post-infection, but that reflected mean 
neonatal plasma concentrations measured following maternal dosing. In 
phytohaemagglutinin (PHA) stimulated cultures M502L exhibited some growth. 
Maintaining NVP and AZT in the culture medium resulted in decreased viral growth over 
time. In contrast to that expected certain donors demonstrated elevated p24 antigen levels 
in the presence of HIV-1 and NVP or AZT. This suggested that cells were more 
conducive to HIV-1 replication either because of cellular activation or due to cellular 
production of cytokines/chemokines. The in vitro study highlighted (i) the differential 
permissiveness of cells from different donors for HIV-1 infection, (ii) different abilities of 
antiretrovirals (ART) to circumvent infection in different individuals and (iii) 
immunomodulatory effects of ART in vitro. 
 
Commencing in Chapter Four we elected to investigate, in vivo, the immunomodulatory 
consequences of HIV-1 exposure and infection in two groups of HIV-1-exposed 
newborns whose mothers either received NVP at the onset of labour or who only received 
NVP as PEP within 72 hours of birth. Short-course antiretroviral drug regimens are 
known to reduce the risk of MTCT of HIV-1 but mechanisms affording protection of such 
interventions remain poorly defined. Since T-cell activation is an important factor in 
productive HIV-1 infection, we tested the hypothesis that single-dose NVP reduces 
immune activation, which in turn reduces the likelihood of transmission. We compared 
concentrations of cord and maternal blood plasma immune activation markers, neopterin, 
β2-microglobulin (β2-m) and soluble L-selectin (sL-selectin) in the two groups of HIV-1-
 ii 
 
exposed newborns and among HIV-unexposed controls. In utero exposure of the infant to 
HIV-1, regardless of NVP exposure, led to demonstrable increases in levels of immune 
activation markers, this being most notable in the presence of pre-existing infection. 
Contrary to what was hypothesized, immune activation was increased by pre-birth 
exposure to single-dose NVP, with this effect being enhanced in infants already infected 
at birth. Our data suggest that reductions in immune activation do not explain 
transmission prevention effects of single-dose NVP. Our data also suggest a biological 
explanation for why HIV-1 infected infants exposed perinatally to antiretroviral drugs 
might experience hastened disease progression, namely that the immunological mileau in 
some HIV-1 infected individuals treated with NVP favours increased HIV-1 replication.  
 
Cytokines and chemokines function to stimulate, or suppress cellular proliferation and 
differentiation and have unique immunomodulatory properties. Furthermore, they have 
the potential to protect against HIV-1 infection or to regulate HIV-1 replication. In 
Chapter Five we therefore questioned whether exposure to HIV-1 or NVP influences 
cytokine/chemokine levels of infants born to HIV-1 infected mothers. We compared 
levels of interleukin (IL)-7, IL-10, stromal cell-derived factor: SDF-1α (CXCL12), 
granulocyte-macrophage colony stimulating factor (GM-CSF), macrophage inflammatory 
protein-1α: MIP-1α (CCL3), macrophage inflammatory protein-1β: MIP-1β (CCL4) and 
regulated upon activation, normal T-cell expressed and secreted: RANTES (CCL5) of the 
two groups of HIV-1-exposed newborns and among the HIV-unexposed controls. HIV-1 
exposure in the absence of single-dose NVP was not found to impact significantly on the 
levels of IL-7, IL-10, GM-CSF, CXCL12, CCL3, CCL4 or CCL5 and single-dose NVP 
had no appreciable effect on these cytokine/chemokine levels. Cord blood plasma levels 
of IL-7, CXCL12 and GM-CSF were found to be independent of mothers’ levels. Single-
dose NVP reduced the ability of cord blood mononuclear cell (CBMC) to produce GM-
CSF spontaneously. Maternal and infant (HIV-1 exposed NVP unexposed) IL-10 levels 
were significantly correlated. Significantly elevated levels of IL-10 were associated with 
pre-existing infection in NVP unexposed newborns. CCL3, CCL4 and CCL5 levels in 
NVP unexposed uninfected infants were not different from those of control infants but 
correlated significantly with IL-7 levels. 
 
HIV-1 specific cellular immune responses are elicited in a proportion of infants born to 
HIV-1 seropositive mothers and have been associated with protection from maternal 
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HIV-1 transmission. In Chapter Six, levels of the immune activation markers neopterin, 
β2-m, sL-selectin, the immunomodulatory and haematopoietic factors IL-7, CXCL12, 
GM-CSF and the immunoregulatory cytokine IL-10 were examined amongst the group of 
newborns, that received NVP as PEP within 72 hours of birth, of which a proportion had 
specific cellular responses to HIV-1 envelope (Env) peptides. It was our aim to determine 
in infants that elicit HIV-1 specific cellular immune responses (Env+) and those that lack 
the specific responses (Env-), whether these factors could predict transmission and 
whether the former group of infants exhibit unique immune features that might 
distinguish them from Env- non-responders. Our data suggested that none of the factors 
tested were predictive of HIV-1 transmission but confirmed that infants with cellular 
responses to HIV-1 envelope peptides were associated with lack of subsequent infection. 
In particular, our data demonstrated an association between HIV-1 specific cellular 
immune responses, lower maternal viral load and lack of infection suggesting that 
sustained exposure to antigen (reduced maternal viral load) may be responsible for the 
strong priming effect. Furthermore, an association between reduced GM-CSF levels and 
the presence of HIV-1 specific responses was demonstrated, which suggested therefore 
that newborn infants that elicited HIV-1 specific cellular immune responses exhibited 
different immune capabilities from those without responses. 
 
Finally, in Chapter Seven we looked at how immune activation and priming impact on 
thymic output of T-cells in newborn infants. Unfortunately, sample volumes of the two 
groups of HIV-1-exposed newborns used in the previous three Chapters became limited 
with the result that we chose to address these questions using anonymously collected cord 
blood samples from infants, some of which were used to supplement the placebo group of 
the the UNAIDS-sponsored clinical trial of short-course zidovudine-lamivudine (AZT-
3TC). At the time the AZT-3TC trial was conducted short-course antiviral prophlyaxis 
was not the standard of care for the prevention of MTCT of HIV-1. The thymus is known 
to be essential for establishing diversity of the T-cell pool, and morphological thymic 
changes and effects on naïve T-cells and T-cell receptor excision circle (TREC) 
concentrations have been reported in studies of HIV-1 infected children and adults. As it 
is not known to what extent in utero exposure to HIV-1 and infection affects T-cell 
division in newborn infants, we elected to determine TREC levels of infants born to HIV-
1 seropositive mothers that were not exposed to antiretrovirals. The impact of increased 
immune activation on TREC levels and the consequence of HIV-1 exposure or infection 
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on circulating levels of IL-7 (raised levels indicative of T-cell depletion) was also 
investigated. HIV-1 exposure or infection did not result in significant losses of TREC. 
TREC levels were not affected by immune activation associated with HIV-1 exposure and 
infection and IL-7 levels were not raised. Infants that elicited HIV-1 specific cellular 
immune responses exhibit TREC levels that were similar to those of infants without HIV-
1 specific responses. These data suggested that newborn infants of HIV-1 seropositive 
mothers demonstrated no altered thymopoietic ability compared to control infants. 
Furthermore, HIV-1 specific immune responses, (indicative of post-thymic memory T-
cell expansion) did not influence thymic output measured in newborn infants.  
 
In conclusion, the in vitro study demonstrated that there is a high degree of variability 
between PBMC isolated from different donors with respect to viral replication and drug 
effectivity which suggests that these phenomena are likely to exist within patient (infant 
as well as adult) populations. While immune activation is considered central to productive 
infection we demonstrated that immune activation is increased by HIV-1 exposure and by 
single-dose NVP. Exposure to HIV-1 alone or with NVP did not influence birth levels of 
IL-7, IL-10, CXCL12, GM-CSF, CCL3, CCL4 and CCL5. Furthermore, levels of these 
factors did not predict infection outcome in the infant. Immune activation and 
haematopoietic growth factors are modulated independently of the mother but maternal 
factors such as IL-10 and exposure to single-dose NVP, which reduces responsiveness of 
CBMC, could impact on the infant. HIV-1 specific cellular immune responses at birth, 
which are elicited in a proportion of infants born to HIV-1 positive mothers, are of 
immunological significance and can predict lack of subsequent infection. Disturbances in 
thymic output are not readily detectable at birth when using TREC to assess de novo T-
cell synthesis, alternatively there is a homeostatic balance between thymic output and 
peripheral T-cell proliferation in newborns of HIV-1 infected mothers. Overall our data 
suggests that (i) there are immune consequences of being born to an HIV-1 positive 
mother, (ii) short-course antiretroviral prophylaxis does impact on the developing 
immune system of the infant and (iii) while the direct effects of single-dose NVP are not 
disputed, there are indirect consequences of NVP exposure on immune cells. Despite the 
consequences of HIV-1 exposure or the result of being born to a HIV-1 seropositive 
mother or exposure to single-dose NVP, our data proposes that the immune system of 
newborn infants is capable of responding as demonstrated by the enhanced immune 
activation. It remains important to determine the correlates of immune protection for the 
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development of novel immuno-therapeutic and vaccine strategies and maternal-infant 
transmission of HIV-1 provides a model which can address questions of protective 
immune processes. Understanding the influence of antiretrovirals on immune processes 
remains an important component of the drug mechanisms, (aside from their direct 
antiretroviral activity), that may underlie reductions in maternal-infant transmission of 
HIV-1. Furthermore, how antiretrovirals influence immune processes and immune 
development (together with exposure to HIV-1/consequences of being born to an HIV-1 
seropositive mother), may impact on subsequent immune responsiveness to infectious 
organisms or childhood vaccines.  
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